Evidence map›Paper›PMID 31491904›Full record

ArticleNanomaterials (Basel, Switzerland)2019

Graphene Nanoplatelets Modified with Amino-Groups by Ultrasonic Radiation of Variable Frequency for Potential Adsorption of Uremic Toxins.

C Cabello-Alvarado, M Andrade-Guel, M Pérez-Alvarez, G Cadenas-Pliego, Dora A Cortés-Hernández, P Bartolo-Pérez, C A Ávila-Orta, V J Cruz-Delgado, A Zepeda-Pedreguera

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Sonochemical Functionalization of SiOMaterials (Basel, Switzerland) · 2025
    Article
  3. Article
  4. The AKI-to-CKD Transition: The Role of Uremic Toxins.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Article
  7. Date Palm Extract (Plants (Basel, Switzerland) · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

C Cabello-AlvaradoCONACYT Research Fellow-Research and Innovation Consortium of the State of Tlaxcala, C.P. 90000 Tlaxcala, Mexico. christian.cabello@ciqa.edu.mx.
M Andrade-GuelCenter for Research in Applied Chemistry (CIQA), Saltillo, 25315 Coahuila, México.
M Pérez-AlvarezCONACYT Research Fellow-Mexican Petroleum Institute, Eje Central Lázaro Cárdenas Norte 152, 07730 Ciudad de México, México.ORCID 0000-0002-1276-4230
G Cadenas-PliegoCenter for Research in Applied Chemistry (CIQA), Saltillo, 25315 Coahuila, México. gregorio.cadenas@ciqa.edu.mx.
Dora A Cortés-HernándezCenter for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV) Saltillo Unit. Av. Industria Metalúrgica #1062 Parque Industrial Saltillo-Ramos Arizpe, 25900 Saltillo, México.ORCID 0000-0001-7822-1493
P Bartolo-PérezCenter for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV) Mérida Unit, Km. 6 Antigua Carretera a Progreso, Apartado postal 73 Cordemex, Mérida, 97310 Yucatán, México.
C A Ávila-OrtaCenter for Research in Applied Chemistry (CIQA), Saltillo, 25315 Coahuila, México. carlos.avila@ciqa.edu.mx.ORCID 0000-0002-2820-0958
V J Cruz-DelgadoCONACYT Research Fellow- Materials Unit, Yucatan Scientific Research Center, A.C., 97205 Mérida, México.ORCID 0000-0003-0891-7764
A Zepeda-PedregueraAutonomous University of Yucatan(UADY), Mérida, 97310 Yucatán, México.
Autonomous University of Yucatán · MXAutonomous University of Tlaxcala · MXCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXInstituto Tecnológico de Saltillo · MXMexican Institute of Petroleum · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a worldwide public health problem. In stages III and IV of CKD, uremic toxins must be removed from the patient by absorption, through a treatment commonly called hemodialysis. Aiming to improve the absorption of uremic toxins, we have studied its absorption in chemically modified graphene nanoplatelets (GNPs). This study involved the reaction between GNPs and diamines with reaction times of 30, 45 and 60 min using ultrasound waves of different amplitudes and frequencies. Functionalized GNPs were analyzed by Fourier Fourier-transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), Scanning electron microscopy and energy dispersitive spectroscopy (SEM-EDS), and Thermogravimetric analysis (TGA). The analysis of the functional groups confirmed the presence of amide and hydroxyl groups on the surface of the GNPs by reactions of diamines with carboxylic acids and epoxides. Adsorption of uremic toxins was determined using equilibrium isotherms, where the maximum percentage of removal of uremic toxins was 97%. Dispersion of modified graphene nanoplatelets was evaluated in water, ethanol and hexane, as a result of this treatment was achieved a good and effective dispersion of diamines-modified graphene nanoplatelets in ethanol and hexane. Finally, the results of hemolysis assays of the modified graphene with amine demonstrated that it was not cytotoxic when using 500 mg/mL. The samples of modified graphene demonstrated low degree of hemolysis (<2%), so this material can be used for in vivo applications such as hemodialysis.

Indexed as

adsorptionsurface modificationultrasounduremic toxins

Identifiers

PMID31491904
PMCPMC6781048
OpenAlexW2971678882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.